Bionomics Ltd Sp ADR (BMICY) 11.1500 $BMICY
Brain Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnncfl/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Neuralstem, Inc. - Bionomics Limited - Critical Outcome Technologies Inc. - Prana Biotechnology Limited - e-Therapeutics plc - AngioChem Inc. - Merrimack Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Kinex Pharmaceuticals, LLC - Nuvilex, Inc. - TAU Therapeutics, LLC - CureFAKtor Pharmaceuticals. LLC - Arrien Pharmaceuticals, LLC - Oncology Research International Limited For more information visit http://www.researchandmarkets.com/research/nn...ain_cancer
MACK: 9.35 (+0.19), STML: 14.80 (+0.46), PRAN: 1.90 (unch), CUR: 2.83 (+0.09)
Bionomics Presents BNC105 Phase II Renal Cancer Trial Biomarker Data
GlobeNewswire - Mon Sep 29, 6:30AM CDT
-- Progression Free Survival at six months by renal cancer patients increased from 36% to 60% for a patient group defined by four biomarkers
BNO: 34.03 (+0.22)
Bionomics Acquires Prestwick Chemical
GlobeNewswire - Tue Sep 23, 6:30AM CDT
-- Pre-existing business integration and strong synergies
BNO: 34.03 (+0.22)
Global Malignant Mesothelioma Therapeutics Pipeline Review 2014 - 11 Companies & 25 Companies
M2 - Fri Sep 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qjk7h/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals Inc. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - BNC-105 - FPI-01 - YS-110 - BIW-8962 - Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - ONCOS-102 - Drug For Mesothelioma - Oshadi D Oshadi R - AEOL-10150 - anetumab ravtansine - LY-3023414 - Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - VS-4718 - VS-5584 - BERTA - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Ad5-SGE-REIC/Dkk3 Gene Therapy - pemetrexed disodium - Vaccine For Cancer - YP-223 - YYP-218 - YP-3 - DP-3975 - Tb-535C - SentoClone For more information visit http://www.researchandmarkets.com/research/8qjk7h/malignant
VSTM: 9.80 (+0.06), LLY: 64.83 (-1.37), EGRX: 12.43 (+0.22)
Bionomics Receives $7.5M 2014 R&D Tax Incentive
GlobeNewswire - Fri Sep 05, 6:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) has received an Australian R&D Tax Incentive payment of $7.5 million following its FY2014 tax return. The incentive refund amount is as recorded in the FY2014 financial report lodged with the ASX on 19 August 2014.
MRK: 55.85 (-0.60), BNO: 34.03 (+0.22)
Bionomics and Merck Enter New Research Collaboration
PR Newswire - Mon Jun 23, 6:17PM CDT
Bionomics Limited (ASX:BNO, ADR:BMICY) announces that it has entered into an exclusive Research Collaboration and License Agreement with Merck, known as MSD outside the United States and Canada, for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions.
MRK: 55.85 (-0.60), BNO: 34.03 (+0.22)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell
CLDX: 17.06 (+1.64), AMGN: 157.19 (+8.99), LLY: 64.83 (-1.37), BMY: 54.20 (+0.67), GSK: 45.10 (-0.27), LPTN: 2.95 (-0.07), FLML: 12.88 (+0.16), MRK: 55.85 (-0.60)
BNC105 Phase II Renal Cancer Trial Results
GlobeNewswire - Tue Mar 18, 5:30PM CDT
Bionomics to Host Webcast at 6:30pm ET TODAY
BNO: 34.03 (+0.22)
Bionomics Wins Awards at Major BioPharma Asia Convention
GlobeNewswire - Thu Mar 13, 6:30AM CDT
Bionomics Limited (ASX:BNO) has been named as the Innovative Asian Biotech of the Year at this week's BioPharma Asia Industry Awards during the BioPharma Asia Convention, at the Suntec Convention and Exhibition Centre in Singapore.
BNO: 34.03 (+0.22)
Bionomics CEO to Present at ROTH Conference
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) CEO and managing director Dr Deborah Rathjen will present a company update at the renowned 26th Annual ROTH Conference in Dana Point, California Monday, March 10, 2014 at 11am PDT at The Ritz Carlton.
BNO: 34.03 (+0.22)
Head And Neck Cancer - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5stc2x/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2013" report to their offering. 'Head And Neck Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. Scope - A snapshot of the global therapeutic scenario for Head And Neck Cancer. - A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Inovio Biomedical Corporation Gilead Sciences, Inc. GenVec, Inc. Piramal Healthcare Limited Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Daewoong Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd. Takara Holdings Inc. Cell Therapeutics, Inc. CEL-SCI Corporation Advaxis, Inc. Bionomics Limited Northwest Biotherapeutics, Inc. Oncolytics Biotech Inc. Curis, Inc. Transgene SA Panacea Biotec Limited and many more.... For more information visit http://www.researchandmarkets.com/research/5s...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CRIS: 1.29 (+0.01), NWBO: 4.93 (+0.11), ONCY: 0.57 (+0.08), CVM: 0.65 (-0.02), LLY: 64.83 (-1.37), BMY: 54.20 (+0.67), INO: 11.38 (+0.07), GILD: 113.45 (+0.86), BPTH: 2.54 (+0.12), NVS: 92.35 (+2.14)
Cognitive Impairment - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jz9l5q/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Merck & Co., Inc. Avineuro Pharmaceuticals, Inc. Novartis AG Chiesi Farmaceutici SpA Laboratoires Pierre Fabre SA Pfizer Inc. Evotec Aktiengesellschaft Lupin Limited Bionomics Limited Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. Mithridion, Inc. Upsher-Smith Laboratories, Inc. Celon Pharma Sp. z o.o. AGY Therapeutics, Inc. PsychoGenics, Inc. QR Pharma, Inc. Siena Biotech S.p.A. SeneXta Therapeutics SA Dart NeuroScience LLC and many more... For more information visit http://www.researchandmarkets.com/research/jz9l5q/cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MRK: 55.85 (-0.60), LLY: 64.83 (-1.37), GSK: 45.10 (-0.27), BMY: 54.20 (+0.67), ATHX: 1.37 (-0.03), NVS: 92.35 (+2.14)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97xbhx/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013" report to their offering. 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). Scope - A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned DURECT Corporation Eli Lilly and Company Athersys, Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Egalet a/s Samyang Corporation Pfizer Inc. Shire Plc Collegium Pharmaceutical, Inc. Bionomics Limited Cortex Pharmaceuticals, Inc. Chelsea Therapeutics, Inc. Yuyu Pharma, Inc. Hisamitsu Pharmaceutical Co., Inc. Theravance, Inc. Suven Life Sciences Ltd. Spectrum Pharmaceuticals, Inc. Curemark, LLC Supernus Pharmaceuticals, Inc. PsychoGenics, Inc. Intra-Cellular Therapies, Inc. Neos Therapeutics, Inc. KemPharm, Inc. For more information visit http://www.researchandmarkets.com/research/97...on_deficit About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SHPG: 197.80 (+1.93), PFE: 29.09 (+0.06), SUPN: 7.85 (+0.27), SPPI: 7.65 (+0.25), LLY: 64.83 (-1.37), THRX: 16.45 (-0.22), DRRX: 0.77 (+0.01), ATHX: 1.37 (-0.03)
Epilepsy - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Epilepsy
M2 - Mon Sep 02, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njthrp/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epilepsy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Acorda Therapeutics, Inc. -Allergan, Inc. -Anavex Life Sciences Corp. -Asklepios BioPharmaceutical, Inc. -Bial - Portela & Ca, S.A. -Bio-Link -Bionomics Limited -Biovista Inc. -Catalyst Pharmaceutical Partners, Inc. -Celentyx Ltd. -Concert Pharmaceuticals, Inc. -D-Pharm Ltd. -Eisai Co., Ltd. -GW Pharmaceuticals plc -H Lundbeck A/S -Knopp Neurosciences Inc. -Kyowa Hakko Kirin Co., Ltd. -Ligand Pharmaceuticals Incorporated -Lipicard Technologies Limited -Marinus Pharmaceuticals, Inc. -Neurelis, Inc. -Novartis AG -NsGene A/S -Pfizer Inc. -Snowdon Inc. -Sun Pharmaceutical Industries Limited -UCB Group -Upsher-Smith Laboratories, Inc. -Valeant Pharmaceuticals International -Vertex Pharmaceuticals Incorporated -Vichem Chemie Research Ltd. -XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/njthrp/epilepsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 182.60 (+0.27), VRTX: 114.07 (+2.48), CPRX: 2.72 (+0.08), PFE: 29.09 (+0.06), ACOR: 35.06 (+0.60), VRX.TO: 146.50 (-0.34), NVS: 92.35 (+2.14)
Brain Cancer - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Brain Cancer
M2 - Tue Aug 13, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qq9tr/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Advaxis, Inc. - Alfacell Corporation - AngioChem Inc. - Antigenics, Inc. - Archer Biosciences, Inc - Basilea Pharmaceutica Ltd. - Bionomics Limited - CK Life Sciences Int'l., (Holdings) Inc. - Cell Therapeutics, Inc. - Critical Outcome Technologies Inc. - DEKK-TEC, Inc. - Diffusion Pharmaceuticals LLC - Dong-A Pharmaceutical Co., Ltd. - e-Therapeutics plc - EpiCept Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hawthorn Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Nanobiotix - Neuralstem, Inc. - Philogen S.p.A. - Prana Biotechnology Limited - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - to-BBB technologies BV - TVAX Biomedical, LLC For more information visit http://www.researchandmarkets.com/research/3q...ain_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SPPI: 7.65 (+0.25), STML: 14.80 (+0.46), AGEN: 3.18 (+0.14), GILD: 113.45 (+0.86), PRAN: 1.90 (unch), CUR: 2.83 (+0.09)
Bionomics Signs Option and License Agreement With Merck
GlobeNewswire - Wed Jul 31, 5:30AM CDT
Bionomics Limited (ASX:BNO) today announced an agreement with Merck, known as MSD outside the United States and Canada, to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain.
MRK: 55.85 (-0.60)
Bionomics Initiates IND-Enabling Studies With BNC101
GlobeNewswire - Mon Jul 29, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated IND-enabling pharmacology and toxicology.
Research and Markets: Gynecological Cancer - Pipeline Review, H1 2013 Features Players Such as Amgen Inc., Bionomics Limited and Novogen Limited
Business Wire - Wed Jun 05, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmb3bd/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering.
Gynecological Cancer - Pipeline Review, H1 2013 Features Players such as Amgen Inc., Bionomics Limited and Novogen Limited
M2 - Wed Jun 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rhvd5/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gynecological Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gynecological Cancer. Gynecological Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scen
CYTK: 3.57 (+0.14), IMMU: 3.79 (+0.03), PFE: 29.09 (+0.06), LLY: 64.83 (-1.37), GSK: 45.10 (-0.27), MRK: 55.85 (-0.60), AZN: 71.43 (+0.67), NVS: 92.35 (+2.14)
Brain Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnncfl/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Neuralstem, Inc. - Bionomics Limited - Critical Outcome Technologies Inc. - Prana Biotechnology Limited - e-Therapeutics plc - AngioChem Inc. - Merrimack Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Kinex Pharmaceuticals, LLC - Nuvilex, Inc. - TAU Therapeutics, LLC - CureFAKtor Pharmaceuticals. LLC - Arrien Pharmaceuticals, LLC - Oncology Research International Limited For more information visit http://www.researchandmarkets.com/research/nn...ain_cancer
MACK: 9.35 (+0.19), STML: 14.80 (+0.46), PRAN: 1.90 (unch), CUR: 2.83 (+0.09)
Bionomics Presents BNC105 Phase II Renal Cancer Trial Biomarker Data
GlobeNewswire - Mon Sep 29, 6:30AM CDT
-- Progression Free Survival at six months by renal cancer patients increased from 36% to 60% for a patient group defined by four biomarkers
BNO: 34.03 (+0.22)
Bionomics Acquires Prestwick Chemical
GlobeNewswire - Tue Sep 23, 6:30AM CDT
-- Pre-existing business integration and strong synergies
BNO: 34.03 (+0.22)
Global Malignant Mesothelioma Therapeutics Pipeline Review 2014 - 11 Companies & 25 Companies
M2 - Fri Sep 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qjk7h/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals Inc. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - BNC-105 - FPI-01 - YS-110 - BIW-8962 - Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - ONCOS-102 - Drug For Mesothelioma - Oshadi D Oshadi R - AEOL-10150 - anetumab ravtansine - LY-3023414 - Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - VS-4718 - VS-5584 - BERTA - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Ad5-SGE-REIC/Dkk3 Gene Therapy - pemetrexed disodium - Vaccine For Cancer - YP-223 - YYP-218 - YP-3 - DP-3975 - Tb-535C - SentoClone For more information visit http://www.researchandmarkets.com/research/8qjk7h/malignant
VSTM: 9.80 (+0.06), LLY: 64.83 (-1.37), EGRX: 12.43 (+0.22)
Bionomics Receives $7.5M 2014 R&D Tax Incentive
GlobeNewswire - Fri Sep 05, 6:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) has received an Australian R&D Tax Incentive payment of $7.5 million following its FY2014 tax return. The incentive refund amount is as recorded in the FY2014 financial report lodged with the ASX on 19 August 2014.
MRK: 55.85 (-0.60), BNO: 34.03 (+0.22)
Bionomics and Merck Enter New Research Collaboration
PR Newswire - Mon Jun 23, 6:17PM CDT
Bionomics Limited (ASX:BNO, ADR:BMICY) announces that it has entered into an exclusive Research Collaboration and License Agreement with Merck, known as MSD outside the United States and Canada, for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions.
MRK: 55.85 (-0.60), BNO: 34.03 (+0.22)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell
CLDX: 17.06 (+1.64), AMGN: 157.19 (+8.99), LLY: 64.83 (-1.37), BMY: 54.20 (+0.67), GSK: 45.10 (-0.27), LPTN: 2.95 (-0.07), FLML: 12.88 (+0.16), MRK: 55.85 (-0.60)
BNC105 Phase II Renal Cancer Trial Results
GlobeNewswire - Tue Mar 18, 5:30PM CDT
Bionomics to Host Webcast at 6:30pm ET TODAY
BNO: 34.03 (+0.22)
Bionomics Wins Awards at Major BioPharma Asia Convention
GlobeNewswire - Thu Mar 13, 6:30AM CDT
Bionomics Limited (ASX:BNO) has been named as the Innovative Asian Biotech of the Year at this week's BioPharma Asia Industry Awards during the BioPharma Asia Convention, at the Suntec Convention and Exhibition Centre in Singapore.
BNO: 34.03 (+0.22)
Bionomics CEO to Present at ROTH Conference
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) CEO and managing director Dr Deborah Rathjen will present a company update at the renowned 26th Annual ROTH Conference in Dana Point, California Monday, March 10, 2014 at 11am PDT at The Ritz Carlton.
BNO: 34.03 (+0.22)
Head And Neck Cancer - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5stc2x/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2013" report to their offering. 'Head And Neck Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. Scope - A snapshot of the global therapeutic scenario for Head And Neck Cancer. - A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Inovio Biomedical Corporation Gilead Sciences, Inc. GenVec, Inc. Piramal Healthcare Limited Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Daewoong Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd. Takara Holdings Inc. Cell Therapeutics, Inc. CEL-SCI Corporation Advaxis, Inc. Bionomics Limited Northwest Biotherapeutics, Inc. Oncolytics Biotech Inc. Curis, Inc. Transgene SA Panacea Biotec Limited and many more.... For more information visit http://www.researchandmarkets.com/research/5s...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CRIS: 1.29 (+0.01), NWBO: 4.93 (+0.11), ONCY: 0.57 (+0.08), CVM: 0.65 (-0.02), LLY: 64.83 (-1.37), BMY: 54.20 (+0.67), INO: 11.38 (+0.07), GILD: 113.45 (+0.86), BPTH: 2.54 (+0.12), NVS: 92.35 (+2.14)
Cognitive Impairment - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jz9l5q/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Merck & Co., Inc. Avineuro Pharmaceuticals, Inc. Novartis AG Chiesi Farmaceutici SpA Laboratoires Pierre Fabre SA Pfizer Inc. Evotec Aktiengesellschaft Lupin Limited Bionomics Limited Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. Mithridion, Inc. Upsher-Smith Laboratories, Inc. Celon Pharma Sp. z o.o. AGY Therapeutics, Inc. PsychoGenics, Inc. QR Pharma, Inc. Siena Biotech S.p.A. SeneXta Therapeutics SA Dart NeuroScience LLC and many more... For more information visit http://www.researchandmarkets.com/research/jz9l5q/cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MRK: 55.85 (-0.60), LLY: 64.83 (-1.37), GSK: 45.10 (-0.27), BMY: 54.20 (+0.67), ATHX: 1.37 (-0.03), NVS: 92.35 (+2.14)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97xbhx/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013" report to their offering. 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). Scope - A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned DURECT Corporation Eli Lilly and Company Athersys, Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Egalet a/s Samyang Corporation Pfizer Inc. Shire Plc Collegium Pharmaceutical, Inc. Bionomics Limited Cortex Pharmaceuticals, Inc. Chelsea Therapeutics, Inc. Yuyu Pharma, Inc. Hisamitsu Pharmaceutical Co., Inc. Theravance, Inc. Suven Life Sciences Ltd. Spectrum Pharmaceuticals, Inc. Curemark, LLC Supernus Pharmaceuticals, Inc. PsychoGenics, Inc. Intra-Cellular Therapies, Inc. Neos Therapeutics, Inc. KemPharm, Inc. For more information visit http://www.researchandmarkets.com/research/97...on_deficit About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SHPG: 197.80 (+1.93), PFE: 29.09 (+0.06), SUPN: 7.85 (+0.27), SPPI: 7.65 (+0.25), LLY: 64.83 (-1.37), THRX: 16.45 (-0.22), DRRX: 0.77 (+0.01), ATHX: 1.37 (-0.03)
Epilepsy - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Epilepsy
M2 - Mon Sep 02, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njthrp/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epilepsy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Acorda Therapeutics, Inc. -Allergan, Inc. -Anavex Life Sciences Corp. -Asklepios BioPharmaceutical, Inc. -Bial - Portela & Ca, S.A. -Bio-Link -Bionomics Limited -Biovista Inc. -Catalyst Pharmaceutical Partners, Inc. -Celentyx Ltd. -Concert Pharmaceuticals, Inc. -D-Pharm Ltd. -Eisai Co., Ltd. -GW Pharmaceuticals plc -H Lundbeck A/S -Knopp Neurosciences Inc. -Kyowa Hakko Kirin Co., Ltd. -Ligand Pharmaceuticals Incorporated -Lipicard Technologies Limited -Marinus Pharmaceuticals, Inc. -Neurelis, Inc. -Novartis AG -NsGene A/S -Pfizer Inc. -Snowdon Inc. -Sun Pharmaceutical Industries Limited -UCB Group -Upsher-Smith Laboratories, Inc. -Valeant Pharmaceuticals International -Vertex Pharmaceuticals Incorporated -Vichem Chemie Research Ltd. -XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/njthrp/epilepsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 182.60 (+0.27), VRTX: 114.07 (+2.48), CPRX: 2.72 (+0.08), PFE: 29.09 (+0.06), ACOR: 35.06 (+0.60), VRX.TO: 146.50 (-0.34), NVS: 92.35 (+2.14)
Brain Cancer - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Brain Cancer
M2 - Tue Aug 13, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qq9tr/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Advaxis, Inc. - Alfacell Corporation - AngioChem Inc. - Antigenics, Inc. - Archer Biosciences, Inc - Basilea Pharmaceutica Ltd. - Bionomics Limited - CK Life Sciences Int'l., (Holdings) Inc. - Cell Therapeutics, Inc. - Critical Outcome Technologies Inc. - DEKK-TEC, Inc. - Diffusion Pharmaceuticals LLC - Dong-A Pharmaceutical Co., Ltd. - e-Therapeutics plc - EpiCept Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hawthorn Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Nanobiotix - Neuralstem, Inc. - Philogen S.p.A. - Prana Biotechnology Limited - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - to-BBB technologies BV - TVAX Biomedical, LLC For more information visit http://www.researchandmarkets.com/research/3q...ain_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SPPI: 7.65 (+0.25), STML: 14.80 (+0.46), AGEN: 3.18 (+0.14), GILD: 113.45 (+0.86), PRAN: 1.90 (unch), CUR: 2.83 (+0.09)
Bionomics Signs Option and License Agreement With Merck
GlobeNewswire - Wed Jul 31, 5:30AM CDT
Bionomics Limited (ASX:BNO) today announced an agreement with Merck, known as MSD outside the United States and Canada, to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain.
MRK: 55.85 (-0.60)
Bionomics Initiates IND-Enabling Studies With BNC101
GlobeNewswire - Mon Jul 29, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated IND-enabling pharmacology and toxicology.
Research and Markets: Gynecological Cancer - Pipeline Review, H1 2013 Features Players Such as Amgen Inc., Bionomics Limited and Novogen Limited
Business Wire - Wed Jun 05, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmb3bd/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering.
Gynecological Cancer - Pipeline Review, H1 2013 Features Players such as Amgen Inc., Bionomics Limited and Novogen Limited
M2 - Wed Jun 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rhvd5/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gynecological Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gynecological Cancer. Gynecological Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scen
CYTK: 3.57 (+0.14), IMMU: 3.79 (+0.03), PFE: 29.09 (+0.06), LLY: 64.83 (-1.37), GSK: 45.10 (-0.27), MRK: 55.85 (-0.60), AZN: 71.43 (+0.67), NVS: 92.35 (+2.14)
